Biotech & Pharma

Gilead Sciences awarded its U.S. media account to Publicis following a competitive review, shifting from previous representation under Interpublic Group (before Omnicom acquisition).

Leadership read: Alliances broaden the commercial surface, and the leadership need follows. Gilead Sciences's partnership in Biotech & Pharma widens demand for commercial and alliance leaders who turn an agreement into realised value. Across Americas, watch whether dedicated senior ownership is put on it; unowned alliances quietly lapse.

curated · 2026-08-19 · context →

Amgen is terminating its partnership with TScan Therapeutics, a T cell therapy company based in Waltham, MA.

Leadership read: Consolidation shifts the leadership question from growth to integration. For Amgen in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Americas, watch whether the integration is properly resourced; deals are won or lost the year after they close.

curated · 2026-08-19 · context →

BioMarin agreed to acquire Alesta Therapeutics for up to $490 million ($275M upfront + $215M in milestones) to add ALE1, a clinical-stage oral therapy for hypophosphatasia (rare genetic bone disease), to its rare disease pipeline.

Leadership read: Consolidation shifts the leadership question from growth to integration. For BioMarin Pharmaceutical Inc. in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Americas, watch whether the integration is properly resourced; deals are won or lost the year after they close.

curated · 2026-08-18 · context →

Twist Bioscience completed a US$300 million follow-on equity offering at US$96/share, upsized from an initially filed US$250 million raise. Concurrent with Q3 2026 results showing US$118.38M revenue and US$35.05M loss, company raised FY2026 guidance to US$456-457M.

Leadership read: Twist Bioscience's raise resets the leadership agenda more than the balance sheet. Capital into Biotech & Pharma buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across Americas.

curated · 2026-08-17 · context →

UCB announces $2 billion investment in a new biomanufacturing campus in Georgia, expected to create 330+ jobs

Leadership read: Market entry is a leadership problem before it is a logistics one. UCB moving into new ground in Biotech & Pharma deepens demand for in-region leaders who can localise the model without diluting it. Across Americas, watch whether senior in-market leadership is appointed early; expansions run remotely rarely hold.

curated · 2026-08-16 · context →

Bora Pharmaceuticals signed partnership with Insilico Medicine for AI drug discovery. Company launched group-wide AI in Manufacturing program (BORA AIM) to improve process efficiency across sites.

Leadership read: Alliances broaden the commercial surface, and the leadership need follows. Bora Pharmaceuticals's partnership in Biotech & Pharma widens demand for commercial and alliance leaders who turn an agreement into realised value. Across Asia, watch whether dedicated senior ownership is put on it; unowned alliances quietly lapse.

curated · 2026-08-14 · context →

Biogen's monoclonal antibody felzartamab received first global approval in China for second-line multiple myeloma treatment, in combination with lenalidomide and dexamethasone.

Leadership read: Biogen's launch shifts talent demand before revenue catches up. In Biotech & Pharma, taking a release to scale rewards product leaders with a commercial edge and operators who build the post-launch motion. Watch whether Biogen backs it with senior go-to-market hires across Asia — that separates a platform move from a one-off.

curated · 2026-08-14 · context →

FDA granted accelerated approval for iberdomide (marketed as Zenbexus), a multiple myeloma treatment for relapsed or refractory patients.

Leadership read: A product move like this reshapes Bristol Myers Squibb's org chart as much as its roadmap. Scaling in Biotech & Pharma rests on product leadership that can carry a launch to adoption and commercial hires who turn early traction into pipeline. The Americas tell is whether senior GTM appointments follow; unsupported launches stall.

curated · 2026-08-13 · context →

Boehringer Ingelheim acquired Evax AG, a Swiss biotech company specializing in equine health, expanding its animal health portfolio.

Leadership read: Consolidation shifts the leadership question from growth to integration. For Boehringer Ingelheim in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across EMEA, watch whether the integration is properly resourced; deals are won or lost the year after they close.

curated · 2026-08-11 · context →

Biogen completed acquisition of RayThera Inc., with the acquired company's lead program now in Phase 1 development.

Leadership read: Consolidation shifts the leadership question from growth to integration. For Biogen in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Americas, watch whether the integration is properly resourced; deals are won or lost the year after they close.

curated · 2026-08-06 · context →

Federal judge approved $35M settlement with healthcare funds over allegations Teva delayed generic versions of asthma inhalers, causing higher prices

Leadership read: Consolidation shifts the leadership question from growth to integration. For Teva Pharmaceuticals in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Americas, watch whether the integration is properly resourced; deals are won or lost the year after they close.

curated · 2026-08-06 · context →

Twist Bioscience priced a $300 million stock offering at $96 per share, indicating successful capital raise in public markets.

Leadership read: Twist Bioscience's raise resets the leadership agenda more than the balance sheet. Capital into Biotech & Pharma buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across Americas.

curated · 2026-08-05 · context →